AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.

 
• By Cathy Kelly
ICER Finds Roxadustat May Be Cost Saving In Non-Dialysis Patients But There's 'High' Degree Of Uncertainty

More from US FDA Performance Tracker

More from Regulatory Trackers